IFIH1 and interstitial lung disease: For example, anti-Mi-2 is associated with classic DM without interstitial lung disease (ILD) or malignancy and with good response to treatment [4]–[6]; anti-155/140 is associated with malignancy-associated or juvenile DM [7]–[10]; and anti-CADM-140/MDA5 is associated with clinically amyopathic DM (CADM) and rapidly progressive-ILD (RP-ILD) that results in poor prognosis [11], [12].